A new study reveals disappointing results on the potential of GLP-1 drugs like Ozempic to treat Parkinson's disease. Despite earlier hopes, a rigorous ...

The US Food and Drug Administration (FDA) rejected three prior regulatory applications before granting approval.

AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

Sanofi has joined a growing list of drugmakers going after alpha-synuclein targeting drugs for Parkinson's disease, licensing a bispecific antibody from South Korea's ABL Bio in a deal that could ...

While patients with Parkinson’s initially start taking oral drugs like levodopa and carbidopa ... patients who cannot have apomorphine, with a list price of £84.70 per vial ahead of discounts.

Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from ...

“Any obesity is a big risk for high blood pressure but, again, abdominal fat is an especially big contributor,” says Chiesa. ...

It’s not a secret that sleep can get more difficult with age — research suggests that up to half of older adults complain of ...

Acadia Pharmaceuticals' forecasted revenues top $1bn in 2025. Find out why ACAD stock is a "Buy" with its profitable outlook ...

A violinist plays for her father. A singer takes requests. In hospitals and hospices, bedside performers offer a new kind of ...

Stay informed with Hindustan Times' live updates! Track the latest lifestyle news including fashion trends, style guide & ...